Completed

Metacognitive Therapy for Health Anxiety: A Randomised Control Trial

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Metacognitive Therapy

+ Wait List

Other
Who is being recruted

Mental Disorders

+ Hypochondriasis

+ Somatoform Disorders

From 18 to 65 Years
+12 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
Study Start: March 2015
See protocol details

Summary

Principal SponsorUniversity of Manchester
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: March 1, 2015

Actual date on which the first participant was enrolled.

Hypochondriasis or severe health anxiety is characterised by excessive, disproportionate and persistent thoughts, behaviour and emotion focused on physical symptoms and/or fear of developing a serious illness. There is often excessive worry about illness or disease in the absence of supporting medical evidence and contrary to continual medical reassurance. The most effective psychological treatments are cognitive and behavioural therapies (CBT). However, CBT has failed to demonstrate consistent gains in the treatment of this disorder. A newer form of psychological therapy, Metacognitive Therapy (MCT) has shown to be more effective than CBT in the treatment of anxiety disorders and depression. MCT is based on the principle that health anxiety is caused by a pattern of extended thinking, this pattern is called the Cognitive Attentional Syndrome (CAS). The CAS is made up of chains of verbal thought in the form of excessive worry about having an illness; a pattern of focusing attention on threat, such as scanning the body for signs of illness and excessive body checking; and coping strategies that have negative effects, such as internet searching for illnesses or trying to block out thoughts of illness. Rather than stopping negative thinking the CAS extends it and leads to the belief that illness is present. To help reduce these symptoms MCT teaches specific techniques that help people develop new ways of experiencing negative thoughts about illnesses, allow them to abandon worry and learn to disengage from unhelpful coping attempts. A recent small study has provided some limited evidence that metacognitive therapy (MCT) can be applied to cases of hypochondriasis and demonstrated that the therapy was associated with improvement in symptoms. To provide future evaluation of MCT in this client group a more definitive trial will be carried out to ascertain the effects of MCT in a larger group when compared to a control group. If the results are positive this will provide a rationale for a larger research study, which will compare MCT with evidence based treatment such as CBT.

Official TitleMetacognitive Therapy for Health Anxiety: A Randomised Control Trial
NCT02404116
Principal SponsorUniversity of Manchester
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

21 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 65 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Mental DisordersHypochondriasisSomatoform Disorders

Criteria

6 inclusion criteria required to participate
Be over 18.

Exceed cut off on BP and WI

Not undergoing any other form of psychological therapy during treatment.

If on medication must be stable six weeks prior to treatment onset.

Show More Criteria

6 exclusion criteria prevent from participating
Be under 18

Not exceeding cut off on BP and WI

Undergone CBT for health anxiety over the past three months.

Having started medication less than four weeks before assessment

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
12 weeks of Metacognitive Therapy

Group II

The Waiting list control will control for time and repeated assessments during an initial 12 week period

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 2 locations

Suspended

University of Central Lancashire

Preston, United KingdomOpen University of Central Lancashire in Google Maps
Suspended

University of Manchester

Manchester, United Kingdom
Completed2 Study Centers
Metacognitive Therapy for Health Anxiety: A Randomised Control Trial | PatLynk